Salut Brunet

Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors

Pau Montesinos, Juan Bergua, Edo Vellenga et al. · Blood · 2008 · 364 citations · Full text

Medicine, Hematology, Oncology +17

Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin

Javier de la Serna, Pau Montesinos, Edo Vellenga et al. · Blood · 2008 · 350 citations · Full text

Medicine, Hematology, Oncology +14

Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome

Miguel Á. Sanz, Pau Montesinos, Chelo Rayón et al. · Blood · 2010 · 336 citations · Full text

Medicine, Oncology, Pharmacology +16

Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group

Albert Oriol, Susana Vives, Jesús María Hernández‐Rivas et al. · Haematologica · 2010 · 292 citations · Full text

Medicine, Oncology, Chemotherapy +14

Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy

Marta Pratcorona, Salut Brunet, Josep Nomdedéu et al. · Blood · 2013 · 282 citations

Medicine, Hematology, Oncology +12